Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder

• Published in: CNS drugs 2023-01, Vol.37 (1), p.93-106
• Main Authors: Kunz, Dieter, Dauvilliers, Yves, Benes, Heike, García-Borreguero, Diego, Plazzi, Giuseppe, Seboek Kinter, Dalma, Coloma, Preciosa, Rausch, Magdalene, Sassi-Sayadi, Mouna, Thein, Stephen
• Format: Article
• Language: English
• Subjects: Adult; Clinical trials; Daytime; Double-Blind Method; Drug dosages; Humans; Imidazoles; Insomnia; Medicine; Medicine & Public Health; Mental disorders; NCT; NCT03679884; Neurology; Neuropeptides; Neurosciences; Orexins; Original; Original Research Article; Patients; Pharmacotherapy; Placebos; Psychiatry; Psychopharmacology; Pyrrolidines - adverse effects; Questionnaires; Safety; Self report; Sleep; Sleep and wakefulness; Sleep disorders; Sleep Initiation and Maintenance Disorders - chemically induced; Sleep Initiation and Maintenance Disorders - drug therapy; Treatment Outcome
• ISSN: 1172-7047; 1179-1934
• DOI: 10.1007/s40263-022-00980-8

Background and Objective Daridorexant is a dual orexin receptor antagonist for the treatment of insomnia. In two phase III, 12-week studies in patients with insomnia disorder, daridorexant improved sleep and daytime functioning while maintaining a favorable safety profile. The objective of this 40-week extension study was to assess the long-term safety and tolerability of daridorexant. Methods Adults with insomnia disorder who completed the 12-week studies were invited to enroll in this double-blind extension study. Patients originally randomised to daridorexant (10 mg/25 mg/50 mg) remained on their respective treatments; patients randomised to placebo were re-randomised to daridorexant 25 mg or placebo. The 40-week treatment period was followed by a 7-day placebo run-out. The primary objective was to assess safety/tolerability. Exploratory objectives were to evaluate the efficacy of daridorexant on sleep (self-reported total sleep time) and daytime functioning (Insomnia Daytime Symptoms and Impacts Questionnaire). Results In total, 804 patients were enrolled in the study, of whom 801 received at least one dose of the study treatment and 550 patients (68.4%) completed the study. Overall incidence of treatment-emergent adverse events was similar across groups (35–40%). Daridorexant did not induce next-morning sleepiness and no withdrawal-related symptoms or rebound were observed after treatment discontinuation. Improvements in sleep and daytime functioning were maintained through to the end of the study and were most pronounced with daridorexant 50 mg. Daridorexant 50 mg, compared with placebo, increased self-reported total sleep time by a least-squares mean of 20.4 (95% confidence interval [CI] 4.2, 36.5), 15.8 (95% CI − 0.8, 32.5) and 17.8 (95% CI − 0.4, 35.9) minutes and decreased (i.e., improved) Insomnia Daytime Symptoms and Impacts Questionnaire total scores by a least-squares mean of − 9.3 (95% CI − 15.1, − 3.6), − 9.5 (95% CI − 15.4, − 3.5) and − 9.1 (95% CI − 15.6, − 2.7), at weeks 12, 24 and 36 of the extension study, respectively. Conclusions Treatment with daridorexant, for up to 12 months, was generally safe and well tolerated. Exploratory efficacy analyses suggest that the sustained improvements in sleep and daytime functioning with daridorexant 50 mg support its use for long-term treatment of insomnia disorder, without concerns of new safety signals. Clinical Trial Registration ClinicalTrials.gov (NCT03679884) [first posted: 21 September, 201